TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Pakistan to conduct trials of Chinese coronavirus vaccine

News Desk (Agence France-Presse)
Karachi, Pakistan
Wed, August 19, 2020

Share This Article

Change Size

Pakistan to conduct trials of Chinese coronavirus vaccine Pakistan regulators have approved final-phase testing of a Chinese-made vaccine against the coronavirus, officials said Tuesday, in the country's first ever clinical trial of its kind. (Shutterstock/Numstocker)

P

akistan regulators have approved final-phase testing of a Chinese-made vaccine against the coronavirus, officials said Tuesday, in the country's first ever clinical trial of its kind.

According to Pakistan's National Institute of Health (NIH), regulators have approved the testing of a vaccine under development by CanSinoBio and the Beijing Institute of Biotechnology China.

The medication is already undergoing Phase 3 trials -- or large-scale testing on humans -- in China, Russia, Chile and Argentina. Saudi Arabia will also take part, NIH said.

"This will be the first ever Phase 3 clinical trial for any vaccine in Pakistan," the NIH said in a statement.

Pakistan's inclusion in the trials would help it secure "preferential vaccine supply and pricing", it added.

The trials will be conducted at several medical facilities across Pakistan, including the large Indus Hospital in Karachi. 

"Hopefully we will come out with the vaccine within three to four months," Abdul Bari, who heads the Indus Hospital, told AFP.

The coronavirus has claimed more than 6,000 lives in Pakistan but cases have been dropping for several weeks.

 

 

 

{

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.